Guiding the success of clinical drug development in metabolic and cardiovascular drug development
In this focused niche market we provide integrated preclinical and scientific consultancy services to optimize drug discovery development and shorten the time to market for new targets and compounds. Our in-house capabilities and innovative customized solutions, combined with our scientific team expertise, provide our partners with reliable and long-lasting R&D collaborations.
We offer the following services :
- Discovery : Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision
- Preclinical development : In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs
- Marketing : Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning
Physiogenex pioneers the development of radiolabeled tracer-based kinetic methods and predictive animal nutritional models. We thus provide our partners with pertinent and reliable discovery and preclinical data forsuccessful strategic decision-making. Physiogenex has rapidly achieved global player status by virtue of its unique expertise, covering complex metabolic disorders associated with diabetes, obesity, lipid disorders (dyslipidemia, hypercholesterolemia) and liver disorders ( NAFLD / NASH), hypertension and cardiovascular diseases.
Physiogenex is an entrepreneurial, science-driven company dedicated to helping pharmaceutical, biotechnology and nutraceutical companies.
For French companies :
Physiogenex is accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR) for 2014 to the end of 2016.
The Ministry of Higher Education and Research delivers the accreditation based on the adequacy of a company’s R&D potential. IR is a tax measure designed to support the R&D expenditures of companies located in France. It is calculated on the basis of R&D expenditures – including those subcontracted to approved outsourced research service providers.